Passage Bio announces 1-for-20 reverse stock split effective July 14, 2025

Passage BIO, Inc.

Reverse split ratio 1-for-20; effective 12:01 a.m. ET on July 14, 2025.
Pre-split shares ~62.4M; post-split ~3.12M shares outstanding.
Action intended to regain Nasdaq minimum $1.00 bid price compliance.
No fractional shares; holders of fractional shares receive rounded-up whole share.
No change to authorized shares (125M), par value ($0.0001), or voting rights.

item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Passage BIO, Inc.: 1-for-20 reverse stock split effective July 14, 2025 (effective 2025-07-14).

Change: charter amendment
Effective: 2025-07-14

Exact text from the filing

On July 11, 2025, Passage Bio, Inc. (the “ Company ”) filed a Certificate of Amendment (the “ Amendment ”) to its Amended and Restated Certificate of Incorporation (the “ Certificate of Incorporation ”) with the Secretary of State of the State of Delaware to implement a 1-for-20 reverse stock split (the “ Reverse Stock Split ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) to be effective as of 12:01 am Eastern time on July 14, 2025 (the “ Effective Time ”).

View on SEC.gov

Browse all governance changes →

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-067561

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.